This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

RAPT Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

RAPT Therapeutics şirketinin kazançlarının yıllık 29% oranında düşmesi, yıllık gelirinin ise yıllık 84.4% oranında artması bekleniyor. EPS'nin yıllık 15.4% oranında düşüşmesi bekleniyor.

Anahtar bilgiler

-29.0%

Kazanç büyüme oranı

-15.44%

EPS büyüme oranı

Biotechs kazanç büyümesi	25.3%
Gelir büyüme oranı	84.4%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	03 Mar 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Seeking Alpha • Jan 20

RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

Summary RAPT Therapeutics, Inc. is being acquired by GSK plc, aka GlaxoSmithKline, for $2.2 billion, driven by its promising anti-IgE antibody ozureprubart. Ozureprubart offers a potential best-in-class profile with extended half-life, enabling dosing every 8–12 weeks versus XOLAIR’s 2–4 weeks. The Phase 2b prestIgE trial is underway for IgE-mediated food allergy, leveraging strong proof-of-concept data in chronic spontaneous urticaria. I maintain a Buy rating on RAPT, citing pipeline progress, the acquisition that happened, and the broad applicability of ozureprubart to IgE-mediated disorders. Read the full article on Seeking Alpha

Analiz Makalesi • Jul 16

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

Summary RAPT Therapeutics' lead candidate, zelnecirnon, is in phase 2 for atopic dermatitis and asthma with very promising ph1b results in atopic dermatitis and potential expansion in multiple indications. Liver failure in a single patient with a complex medical history resulted in a clinical hold by the FDA, leaving RAPT no choice but to unblind both ongoing ph2 studies. The probability that zelnecirnon caused the hepatic failure is low considering alternative explanations and no prior preclinical/clinical evidence of liver toxicity. If ph1b results are replicated, I expect the ph2 readout to be positive with available patients, despite premature halting of the trial. Subsequently, I expect the lifting of the FDA clinical hold. Read the full article on Seeking Alpha

Analiz Makalesi • Feb 21

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Sep 12

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • May 10

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Feb 07

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analiz Makalesi • Oct 12

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Jan 25

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Oct 15

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Jun 08

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analiz Makalesi • Mar 15

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:RAPT - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	N/A	-220	-183	N/A	4
12/31/2027	N/A	-162	-142	N/A	4
12/31/2026	N/A	-91	-99	N/A	4
12/31/2025	N/A	-83	-79	N/A	4
9/30/2025	N/A	-106	-87	-87	N/A
6/30/2025	N/A	-106	-92	-92	N/A
3/31/2025	N/A	-117	-109	-109	N/A
12/31/2024	N/A	-130	-83	-83	N/A
9/30/2024	N/A	-107	-101	-101	N/A
6/30/2024	N/A	-120	-105	-105	N/A
3/31/2024	N/A	-118	-106	-106	N/A
12/31/2023	N/A	-117	-98	-97	N/A
9/30/2023	N/A	-109	-93	-92	N/A
6/30/2023	N/A	-99	-89	-87	N/A
3/31/2023	1	-93	-75	-74	N/A
12/31/2022	2	-84	-72	-71	N/A
9/30/2022	2	-79	-70	-69	N/A
6/30/2022	3	-76	-65	-64	N/A
3/31/2022	3	-73	-63	-63	N/A
12/31/2021	4	-69	-62	-61	N/A
9/30/2021	4	-64	-56	-56	N/A
6/30/2021	5	-60	-54	-53	N/A
3/31/2021	5	-56	-46	-46	N/A
12/31/2020	5	-53	-41	-40	N/A
9/30/2020	4	-53	-31	-31	N/A
6/30/2020	2	-49	-33	-33	N/A
3/31/2020	1	-47	-36	-36	N/A
12/31/2019	N/A	-43	-36	-35	N/A
9/30/2019	N/A	-39	-42	-39	N/A
6/30/2019	N/A	-40	N/A	-36	N/A
3/31/2019	N/A	-37	N/A	-34	N/A
12/31/2018	N/A	-36	N/A	-33	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: RAPT önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: RAPT önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: RAPT önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: RAPT gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: RAPT gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: RAPT 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/03/05 18:47
Gün Sonu Hisse Fiyatı	2026/03/02 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

RAPT Therapeutics, Inc. 7 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Gao Yi Chen	Berenberg
Guyn Kim	BMO Capital Markets Equity Research
Zegbeh Jallah	Capital One Securities, Inc.

This company has been acquired

RAPT Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 18% to US$18.14

Price target decreased by 21% to US$33.63

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$50.29

Recent updates

GSK plc (LSE:GSK) completed the acquisition of 93.4% stake in RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

GSK plc (LSE:GSK) entered a definitive agreement to acquire RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

RAPT Therapeutics, Inc. Announces William Ho Leaves as Chief Medical Officer on December 31, 2025

RAPT Therapeutics, Inc. Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies

RAPT Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.00002 million.

RAPT Therapeutics, Inc. and Shanghai Jeyou Pharmaceutical Co., Ltd. Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

We're Keeping An Eye On RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Rate

RAPT Therapeutics, Inc. Announces Board and Committee Appointments

RAPT Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Minimum Closing Bid Price Rule

RAPT Therapeutics, Inc., Annual General Meeting, May 29, 2025

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Wendye R. Robbins Does Not Stand for Election as Director of Rapt Therapeutics, Inc

Still Cautious Over RAPT Therapeutics' Fresh Start With RPT904

RAPT Therapeutics, Inc. Announces Board Changes

RAPT Therapeutics, Inc. announced that it expects to receive $149.976555 million in funding from a group of investors

Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?

Rapt Therapeutics Approves Reduction to Their Workforce

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

Price target decreased by 18% to US$18.14

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

RAPT Therapeutics, Inc., Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

Price target decreased by 21% to US$33.63

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

RAPT Therapeutics, Inc. Announces FDA Verbally Notifies Clinical Hold on its Phase 2b Trial of Zelnecirnon (RPT193) in Atopic Dermatitis and its Phase 2a Trial in Asthma

New major risk - Revenue and earnings growth

RAPT Therapeutics, Inc. Appoints Nipun Davar as Senior Vice President of Technical Operations

RAPT Therapeutics, Inc. Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

New major risk - Revenue and earnings growth

New minor risk - Share price stability

RAPT Therapeutics, Inc. Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

New major risk - Revenue and earnings growth

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

First quarter 2023 earnings released: US$0.77 loss per share (vs US$0.69 loss in 1Q 2022)

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Chief Medical Officer notifies of intention to sell stock

Insider recently bought US$98k worth of stock

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Chief Medical Officer notifies of intention to sell stock

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Insufficient new directors

Chief Medical Officer notifies of intention to sell stock

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.63 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.63 loss in 3Q 2021)

Chief Medical Officer notifies of intention to sell stock

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$50.29

Price target decreased to US$53.00

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently bought US$77k worth of stock

Consensus forecasts updated

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer exercised options and sold US$69k worth of stock

Chief Scientific Officer exercised options and sold US$65k worth of stock

Third quarter 2021 earnings released: US$0.63 loss per share (vs US$0.60 loss in 3Q 2020)